A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune Inc.
Replimune Inc.
The Netherlands Cancer Institute
Cancer Research UK
Cancer Research UK
Cancer Research UK
Linnaeus Therapeutics, Inc.
Second Affiliated Hospital of Guangzhou Medical University